PE20060826A1 - OLEOPHINIC DERIVATIVE OF 8-AZONIABICICLO [3.2.1] OCTANE AND THE PHARMACEUTICAL COMBINATION THAT INCLUDES IT - Google Patents

OLEOPHINIC DERIVATIVE OF 8-AZONIABICICLO [3.2.1] OCTANE AND THE PHARMACEUTICAL COMBINATION THAT INCLUDES IT

Info

Publication number
PE20060826A1
PE20060826A1 PE2005001396A PE2005001396A PE20060826A1 PE 20060826 A1 PE20060826 A1 PE 20060826A1 PE 2005001396 A PE2005001396 A PE 2005001396A PE 2005001396 A PE2005001396 A PE 2005001396A PE 20060826 A1 PE20060826 A1 PE 20060826A1
Authority
PE
Peru
Prior art keywords
octane
pharmaceutical combination
dry powder
preferred
powder inhaler
Prior art date
Application number
PE2005001396A
Other languages
Spanish (es)
Inventor
Dramane Ibrahim Laine
Michael R Palovich
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of PE20060826A1 publication Critical patent/PE20060826A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A UNA COMBINACION FARMACEUTICA QUE COMPRENDE UN ANTAGONISTA DEL RECEPTOR DE ACETILCOLINA MUSCARINICO TAL COMO: BROMURO DE (3-ENDO)-3-(2,2-DI-2-TIENILETENIL)-8,8-DIMETIL-8-AZONIABICICLO[3.2.1]OCTANO Y UNO O MAS INGREDIENTES ACTIVOS TAL COMO i) UN AGONISTA ADRENORRECEPTOR ß-2 SIENDO PREFERIDO XINAFOATO DE SALMETEROL; Y ii) UN AGENTE CORTICOSTEROIDE ANTIINFALAMATORIO SIENDO PREFERIDO PROPIONATO DE FLUTICASONA. ESTA COMBINACION ES UTIL PARA EL TRATAMIENTO EN LA ENFERMEDAD PULMONAR OBSTRUCTIVA CRONICA, BRONQUITIS CRONICA, ASMA, OBSTRUCCION RESPIRATORIA CRONICA, FIBROSIS PULMONAR, EFISEMA PULMONAR Y RINITIS ALERGICA. LA ADMINISTRACION SE REALIZA MEDIANTE UN DISPENSADOR SELECCIONADO DE UN INHALADOR DE POLVO SECO EN UN DEPOSITO, UN INHALADOR DE POLVO SECO EN MULTIPLES DOSIS O EN DOSIS MEDIDAS, CON UNA DURACION DE ACCION DE 12 HORAS A MAS, PARA UNA DOSIS DE 1 MGREFERS TO A PHARMACEUTICAL COMBINATION INCLUDING AN ANTAGONIST OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR SUCH AS: (3-ENDO) -3- (2,2-DI-2-THENYLETHENYL) -8,8-DIMETHYL-8-AZONIABICICLE BROMIDE [ 3.2.1] OCTANE AND ONE OR MORE ACTIVE INGREDIENTS SUCH AS i) A ß-2 ADRENORECEPTOR AGONIST, SALMETEROL XINAFOATE BEING PREFERRED; AND ii) AN ANTI-INFLAMMATORY CORTICOSTEROID AGENT, FLUTICASONE PROPIONATE BEING PREFERRED. THIS COMBINATION IS USEFUL FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, CHRONIC BRONCHITIS, ASTHMA, CHRONIC RESPIRATORY OBSTRUCTION, PULMONARY FIBROSIS, PULMONARY EPHYSEMA AND ALLERGIC RHINITIS. ADMINISTRATION IS CARRIED OUT THROUGH A SELECTED DISPENSER OF A DRY POWDER INHALER IN A TANK, A DRY POWDER INHALER IN MULTIPLE DOSES OR IN MEASURED DOSES, WITH AN ACTION DURATION OF 12 HOURS OR MORE, FOR A DOSE OF 1 MG

PE2005001396A 2004-12-06 2005-12-01 OLEOPHINIC DERIVATIVE OF 8-AZONIABICICLO [3.2.1] OCTANE AND THE PHARMACEUTICAL COMBINATION THAT INCLUDES IT PE20060826A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US63361804P 2004-12-06 2004-12-06

Publications (1)

Publication Number Publication Date
PE20060826A1 true PE20060826A1 (en) 2006-10-08

Family

ID=36578468

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005001396A PE20060826A1 (en) 2004-12-06 2005-12-01 OLEOPHINIC DERIVATIVE OF 8-AZONIABICICLO [3.2.1] OCTANE AND THE PHARMACEUTICAL COMBINATION THAT INCLUDES IT

Country Status (5)

Country Link
AR (1) AR052145A1 (en)
PE (1) PE20060826A1 (en)
TW (1) TW200633715A (en)
UY (1) UY29245A1 (en)
WO (1) WO2006062931A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20050250A1 (en) 2003-07-17 2005-04-08 Glaxo Group Ltd ANTAGONISTS OF ACETYLCHOLIN MUSCARINAL RECEPTORS
ATE494285T1 (en) 2003-10-14 2011-01-15 Glaxo Group Ltd MUSCARINE ACETYLCHOLINE RECEPTOR ANTAGONISTS
AP2006003575A0 (en) 2003-10-17 2006-04-30 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists.
TW200524577A (en) 2003-11-04 2005-08-01 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
EP1725564A4 (en) 2004-03-17 2007-09-12 Glaxo Group Ltd M3 muscarinic acetylcholine receptor antagonists
AR050902A1 (en) 2004-04-27 2006-12-06 Glaxo Group Ltd QUINUCLIDINE COMPOSITE, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USOPRATION TO PREPARE SUCH COMPOSITION
EP1747219A4 (en) 2004-05-13 2010-05-26 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists field of the invention
EP1957075A4 (en) 2004-11-15 2009-11-18 Glaxo Group Ltd Novel m3 muscarinic acetylcholine receptor antagonists
WO2007022351A2 (en) 2005-08-18 2007-02-22 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
EP2080523A1 (en) * 2008-01-15 2009-07-22 CHIESI FARMACEUTICI S.p.A. Compositions comprising an antimuscarinic and a long-acting beta-agonist
TW200946526A (en) 2008-02-06 2009-11-16 Glaxo Group Ltd Dual pharmacophores-PDE4-muscarinic antagonistics
UY31636A1 (en) 2008-02-06 2009-08-03 DUE PHARMACOPHORES-MUSCARINIC ANTAGONISTS OF PDE4
UY31637A1 (en) 2008-02-06 2009-08-03 DUE PHARMACOPHORES-MUSCARINIC ANTAGONISTS OF PDE4
DK2400950T3 (en) 2009-02-26 2019-07-29 Glaxo Group Ltd PHARMACEUTICAL FORMULA comprising 4 - {(1 R) -2 - [(6- {2 - [(2,6-DICHLORBENZYL) OXY] ETHOXY} HEXYL) AMINO] -1-HYDROXYETHYL} -2- (HYDROXYMETHYL) PHENOL
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
US20140113888A1 (en) * 2011-06-08 2014-04-24 Glaxo Group Limited Novel Combination of Therapeutic Agents
JP6267685B2 (en) 2012-04-13 2018-01-24 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Aggregated particles
GB201222679D0 (en) 2012-12-17 2013-01-30 Glaxo Group Ltd Pharmaceutical combination products

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1140998B (en) * 1980-06-18 1986-10-10 Valeas Ind Chimica E Farmaceut ENDO-8-METHYL-8-SIN-ALCHIL-8-AZONIABICYCLE OPEN SALTS PAR. SQUARE 3.2.1. CLOSED PAR. QUADRATA-OTTAN-3-ALCHILCARBOSSILATI, PROCESS FOR THEIR PREPARATION AND THERAPEUTIC COMPOSITIONS THAT CONTAIN THEM AS AN ACTIVE INGREDIENT
IT1194343B (en) * 1983-07-26 1988-09-14 Valeas Spa ENDO-8,8-DIALKYL-8-AZONIABICICLO SALTS (3.2.1) OTTAN-6,7-ESSO-EPOSSI-3-ALCHILCARBOSSILATI, PROCESS FOR THEIR PREPARATION AND THERAPEUTIC COMPOSITIONS THAT CONTAIN THEM AS AN ACTIVE INGREDIENT
DE19528145A1 (en) * 1995-08-01 1997-02-06 Boehringer Ingelheim Kg New drugs and their use
US20030013675A1 (en) * 2001-05-25 2003-01-16 Boehringer Ingelheim Pharma Kg Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases

Also Published As

Publication number Publication date
WO2006062931A3 (en) 2007-04-19
UY29245A1 (en) 2006-05-31
AR052145A1 (en) 2007-03-07
TW200633715A (en) 2006-10-01
WO2006062931A2 (en) 2006-06-15

Similar Documents

Publication Publication Date Title
PE20060826A1 (en) OLEOPHINIC DERIVATIVE OF 8-AZONIABICICLO [3.2.1] OCTANE AND THE PHARMACEUTICAL COMBINATION THAT INCLUDES IT
Anderson et al. Inhaled medicines: past, present, and future
ES2468840T7 (en) Combination therapy for COPD
PE20091672A1 (en) NEW DOSAGE AND FORMULATION
JP2020079295A (en) Methods of treating autoimmune, respiratory and inflammatory disorders by inhalation of roflumilast n-oxide
US20070202055A1 (en) Pharmaceutical Formulations
PT1713473E (en) The combination of anticholinergics and glucocorticoids for the long-term treatment of asthma and copd
JP2006501253A (en) Pharmaceutical composition for inhalation containing a novel anticholinergic agent together with corticosteroid and beta mimetic
US20090238771A1 (en) Pharmaceutical formulations
WO2012110770A2 (en) Pharmaceutical composition
ES2961242T3 (en) Combination therapy for COPD
EP1819329A2 (en) Pharmaceutical formulations comprising pleconaril for the treatment of airway diseases
RS52940B (en) Pharmaceutical solution formulations for pressurised metered dose inhalers
CA2585122A1 (en) M1 and/or m3 receptor antagonists in combination with other actives for treating respiratory disorders
WO2007095039A2 (en) Pharmaceutical formulations
JOP20200314A1 (en) Stable pharmaceutical compositions for pressurized metered dose inhalers
ES2467928T3 (en) Aerosol formulation for COPD
UY30935A1 (en) COMBINATION: -ANTAGONIST OF THE CHEMIOQUINE RECEIVER 1 (CCR1) -AGONIST OF THE GLUCOCORTICOID RECEPTOR- OPTIONALLY AGONIST B (BETA) 2, - PHARMACEUTICAL COMPOSITION CONTAINING IT - APPLICATIONS.
JP2008509196A (en) Inhalable drugs containing corticosteroids, beta mimetics and novel anticholinergics
IL155676A (en) Liquid, propellant-free pharmaceutical preparation containing a tiotropium salt and another active substance and its use in the manufacture of a medicament for treating asthma or copd
JP2008538758A (en) Pharmaceutical composition for inhalation containing beta-receptor stimulant and steroid in addition to anticholinergic
EP1654001A2 (en) Medicaments for inhalation comprising steroids and a betamimetic
JP2006517216A (en) Novel pharmaceutical composition based on an anticholinergic agent and a TACE inhibitor
EP3458156A1 (en) Materials and methods for treating chronic cough
NZ613915B2 (en) Combination of glycopyrrolate, fluticasone and indacaterol

Legal Events

Date Code Title Description
FC Refusal